Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia

Annals of Hematology

Volumn 94, Issue 5, 2015, Pages 883-885

  Abraham, Ajay ^a   Devasia, Anup J ^a   Varatharajan, Savitha ^a   Karathedath, Sreeja ^a   Balasubramanian, Poonkuzhali ^a   Mathews, Vikram ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; CASE REPORT; ENZYMOLOGY; HUMAN; MALE; METABOLISM;

ADULT; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE;

EID: 84930322683     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2254-2     Document Type: Letter

References (11)

1. Rowe JM (2009) Optimal induction and post-remission therapy for AML in first remission. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program:396-405. doi:10.1182/asheducation-2009.1.396
2. Kaspers GJ, Zwaan CM (2007) Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 92(11):1519–1532
3. Galmarini CM, Thomas X, Graham K, El Jafaari A, Cros E, Jordheim L, Mackey JR, Dumontet C (2003) Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol 122(1):53–60
4. Cohen SS (1976) The lethality of aranucleotides. Med Biol 54(5):299–326
5. Abraham A, Varatharajan S, Abbas S, Zhang W, Shaji RV, Ahmed R, George B, Srivastava A, Chandy M, Mathews V, Balasubramanian P (2012) Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics 13(3):269–282. doi:10.2217/pgs.11.149
6. Braess J, Pfortner J, Kern W, Hiddemann W, Schleyer E (1999) Cytidine deaminase—the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells. Ann Hematol 78(11):514–520
7. Ciccolini J, Dahan L, Andre N, Evrard A, Duluc M, Blesius A, Yang C, Giacometti S, Brunet C, Raynal C, Ortiz A, Frances N, Iliadis A, Duffaud F, Seitz JF, Mercier C (2010) Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol 28(1):160–165
8. Mercier C, Raynal C, Dahan L, Ortiz A, Evrard A, Dupuis C, Blesius A, Duluc M, Franceschini F, Giacometti S, Salas S, Milano G, Favre R, Seitz JF, Ciccolini J (2007) Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 17(10):841–844
9. Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM (2009) Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol 144(3):388–394. doi:10.1111/j.1365-2141.2008.07461.x
10. Forghieri F, Luppi M, Morselli M, Potenza L (2007) Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients. Haematologica 92(9):e85–90
11. Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW (2004) The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res 64(2):728–735